scholarly journals P48.11 Anlotinib Versus Chemotherapy as a Third-Line or Further Treatment for Advanced Small Cell Lung Cancer

2021 ◽  
Vol 16 (3) ◽  
pp. S504
Author(s):  
Y. Wang ◽  
X. Ling ◽  
S. Cao ◽  
J. Li ◽  
Y. Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Third Line

Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis

2014 ◽  
Vol 15 (2) ◽  
pp. 110-118 ◽  
Author(s):  
Demetrios Simos ◽  
Golmehr Sajjady ◽  
Melissa Sergi ◽  
Mun Sem Liew ◽  
Raffaele Califano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Third Line ◽  
Line Chemotherapy

P40.19 Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer

2021 ◽  
Vol 16 (10) ◽  
pp. S1078
Author(s):  
T. Beninato ◽  
S. Manglaviti ◽  
E. Zattarin ◽  
G. Apollonio ◽  
E. Galli ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Third Line ◽  
Line Chemotherapy

scholarly journals Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

2012 ◽  
Vol 7 (10) ◽  
pp. 1594-1601 ◽  
Author(s):  
Vassiliki A. Papadimitrakopoulou ◽  
Jean-Charles Soria ◽  
Annette Jappe ◽  
Valentine Jehl ◽  
Judith Klimovsky ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals Combination of bevacizumab and dual immunotherapy for extensive-disease small-cell lung cancer: a case report

Immunotherapy ◽  
2021 ◽  
Author(s):  
Lei Song ◽  
Rengui Zhou ◽  
Xiangyong Li ◽  
Dejian Pan
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Survival Time ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
The Third ◽  
Third Line

Small-cell lung cancer (SCLC) is sensitive to chemoradiotherapy but remains to have a poor prognosis. In the immunotherapy era, chemotherapy combined with PD-L1 inhibitors has become a new first-line treatment option for advanced SCLC. The CheckMate 032 study combined a PD-1 blockade and a CTLA-4 inhibitor and found that this dual immunotherapy might be a positive treatment choice for SCLC. In our case, the patient with advanced SCLC received bevacizumab combined with dual immunotherapy over the third line with more than 12 months survival time. The overall survival time was 21.5 months from the start of the third-line treatment and 39 months from the time of extensive-disease SCLC diagnosis. The combination of a VEGF blockade and a dual immunotherapy in SCLC resulted in synergistic treatment effects. Therefore, bevacizumab might be a better adjuvant, either combined with chemotherapy or dual immunotherapy, for patients with persistent disease progression after undergoing immunotherapy.

Second and third line treatment in non-small cell lung cancer

2009 ◽  
Vol 71 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Adolfo Favaretto ◽  
Giulia Pasello ◽  
Cristina Magro ◽  
Clorinda Schettino ◽  
Cesare Gridelli
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
Third Line Treatment
Sign in / Sign up

Export Citation Format

Share Document